Advances in the application of regional citrate anticoagulation for continuous renal replacement therapy in patients with liver failure
10.3760/cma.j.issn.1007-3418.2018.07.015
- VernacularTitle: 局部枸橼酸抗凝在肝衰竭患者进行持续肾脏替代治疗中的应用进展
- Author:
Qiqi NING
1
;
Qinghua MENG
;
Yueke ZHU
Author Information
1. Department of Critical Care Medicine of Liver Diseases, Beijing You’An Hospital, Capital Medical University, Beijing 100069, China
- Publication Type:Review
- Keywords:
Liver failure;
Renal replacement therapy;
Citrate anticoagulation
- From:
Chinese Journal of Hepatology
2018;26(7):549-552
- CountryChina
- Language:Chinese
-
Abstract:
Currently, continuous renal replacement therapy (CRRT) is one of the most important means of organ support methods in critical care medicine. Anticoagulation is an essential part of the treatment process due to its prolonged duration. Patients with liver failure often have coagulation dysfunction and heparin anticoagulant can increase the risk of bleeding, but without heparin anticoagulant, coagulation can easily occur. In addition, an increased volumetric load, hemodynamic instability, nursing workload and other problems are major issues. Therefore, regional citrate anticoagulation (RCA) is the main anticoagulant method for CRRT therapy in patients with liver failure. This article reviews the mechanism, indications, advantages and disadvantages of using RCA to CRRT in hepatic failure.
